Login to Your Account

Other News To Note

Tuesday, June 26, 2012

• MAP Pharmaceuticals Inc., of Mountain View, Calif., said it plans to resubmit its new drug application for Levadex (dihydroergotamine) inhalation aerosol for the acute treatment of migraine in adults in the late third quarter/early fourth quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription